# Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

> **NCT02864953** · PHASE3 · TERMINATED · sponsor: **Remedy Pharmaceuticals, Inc.** · enrollment: 535 (actual)

## Conditions studied

- Brain Edema
- Stroke, Acute

## Interventions

- **DRUG:** BIIB093
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02864953
- **Lead sponsor:** Remedy Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-29
- **Primary completion:** 2023-08-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 535 (ACTUAL)
- **Why stopped:** Early completed to operational challenges and other strategic considerations, not for efficacy or safety reasons
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864953, "Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02864953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*